JP7572734B2 - ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト - Google Patents

ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト Download PDF

Info

Publication number
JP7572734B2
JP7572734B2 JP2022520473A JP2022520473A JP7572734B2 JP 7572734 B2 JP7572734 B2 JP 7572734B2 JP 2022520473 A JP2022520473 A JP 2022520473A JP 2022520473 A JP2022520473 A JP 2022520473A JP 7572734 B2 JP7572734 B2 JP 7572734B2
Authority
JP
Japan
Prior art keywords
methyl
compound
pyran
tetrahydro
pyrrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022520473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550459A5 (https=
JP2022550459A (ja
Inventor
クレイグ ダブリュー リンズリー
ピー ジェフリー コン
アーロン エム ベンダー
マシュー スポック
チャンホ ハン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of JP2022550459A publication Critical patent/JP2022550459A/ja
Publication of JP2022550459A5 publication Critical patent/JP2022550459A5/ja
Application granted granted Critical
Publication of JP7572734B2 publication Critical patent/JP7572734B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2022520473A 2019-10-04 2020-10-02 ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト Active JP7572734B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962910863P 2019-10-04 2019-10-04
US62/910,863 2019-10-04
PCT/US2020/053942 WO2021067696A1 (en) 2019-10-04 2020-10-02 Antagonists of the muscarinic acetylcholine receptor m4

Publications (3)

Publication Number Publication Date
JP2022550459A JP2022550459A (ja) 2022-12-01
JP2022550459A5 JP2022550459A5 (https=) 2023-10-11
JP7572734B2 true JP7572734B2 (ja) 2024-10-24

Family

ID=75337550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520473A Active JP7572734B2 (ja) 2019-10-04 2020-10-02 ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト

Country Status (7)

Country Link
US (1) US12319701B2 (https=)
EP (1) EP4037677B1 (https=)
JP (1) JP7572734B2 (https=)
AU (1) AU2020358000A1 (https=)
CA (1) CA3155864A1 (https=)
ES (1) ES3057371T3 (https=)
WO (1) WO2021067696A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018300980A1 (en) 2017-07-12 2020-01-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
IL273924B2 (en) 2017-10-20 2024-07-01 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
US20230183218A1 (en) * 2020-04-24 2023-06-15 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
US20240174655A1 (en) * 2021-04-02 2024-05-30 Vanderbilt University Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4
WO2022261427A1 (en) * 2021-06-11 2022-12-15 Vanderbilt University (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders
TW202319055A (zh) 2021-07-21 2023-05-16 日商安斯泰來製藥股份有限公司 縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015027204A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2019014427A1 (en) 2017-07-12 2019-01-17 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
WO2019079783A1 (en) 2017-10-20 2019-04-25 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1984353T3 (en) 2006-01-23 2016-03-14 Amgen Inc Aurorakinasemodulatorer and method of use
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
WO2007124181A2 (en) 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
WO2011149995A1 (en) 2010-05-25 2011-12-01 Abbott Laboratories Novel substituted octahydrocyclopenta [c]pyrrol-4-amines as calcium channel blockers
EP3416639B1 (en) 2016-02-16 2022-06-08 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
SMT202000554T1 (it) * 2016-09-02 2020-11-10 Suven Life Sciences Ltd Modulatori allosterici positivi del recettore muscarinico m1
WO2019089676A1 (en) * 2017-10-31 2019-05-09 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
IL276411B2 (en) 2018-02-02 2024-04-01 Univ Vanderbilt M4 muscarinic acetylcholine receptor antagonists
AU2020402978A1 (en) 2019-12-10 2022-06-23 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
WO2021119254A1 (en) 2019-12-10 2021-06-17 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
US20230183218A1 (en) 2020-04-24 2023-06-15 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
EP4139303A1 (en) 2020-04-24 2023-03-01 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
CA3199786A1 (en) 2020-11-18 2022-05-27 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
EP4491228A3 (en) 2020-12-22 2025-04-23 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
CN116669737A (zh) 2020-12-22 2023-08-29 范德堡大学 毒蕈碱型乙酰胆碱受体m4的拮抗剂
US20240174655A1 (en) 2021-04-02 2024-05-30 Vanderbilt University Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4
WO2022216655A1 (en) 2021-04-05 2022-10-13 Vanderbilt University N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders
WO2022261427A1 (en) 2021-06-11 2022-12-15 Vanderbilt University (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015027204A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2019014427A1 (en) 2017-07-12 2019-01-17 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
WO2019079783A1 (en) 2017-10-20 2019-04-25 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4

Also Published As

Publication number Publication date
US12319701B2 (en) 2025-06-03
WO2021067696A1 (en) 2021-04-08
EP4037677A4 (en) 2023-05-03
EP4037677A1 (en) 2022-08-10
EP4037677B1 (en) 2025-09-24
ES3057371T3 (en) 2026-03-02
US20240083907A1 (en) 2024-03-14
AU2020358000A1 (en) 2022-04-07
CA3155864A1 (en) 2021-04-08
JP2022550459A (ja) 2022-12-01

Similar Documents

Publication Publication Date Title
AU2023202086B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
JP7572734B2 (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
EP3732163A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP2023506740A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
JP2023522951A (ja) ムスカリンアセチルコリン受容体ｍ４のアンタゴニストとしての縮合置換ヒドロピロール
JP2023522959A (ja) ムスカリンアセチルコリン受容体ｍ４のアンタゴニストとしての縮合置換ヒドロピロール
EP4267569B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP2023506741A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
JP2024543973A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
JP2023549534A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
WO2022261427A1 (en) (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders
WO2022036177A1 (en) Antagonists of the muscarinic acetylcholine receptor m4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230929

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240815

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241004

R150 Certificate of patent or registration of utility model

Ref document number: 7572734

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150